Trial · NCT02291861
Results by group88
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 88
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model For Repeated Measures (MMRM) | Placebo | -1.4 | Standard Error 0.41 | units on a scale | |
| Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model For Repeated Measures (MMRM) | SD-809 12 mg/Day | -2.1 | Standard Error 0.42 | units on a scale | |
| Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model For Repeated Measures (MMRM) | SD-809 24 mg/Day | -3.2 | Standard Error 0.45 | units on a scale | |
| Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model For Repeated Measures (MMRM) | SD-809 36 mg/Day | -3.3 | Standard Error 0.42 | units on a scale | |
| Percentage of Patients Considered a Treatment Success at Week 12 as Assessed by the Clinical Global Impression of Change (CGIC) | Placebo | 26 | 95% Confidence Interval 16.3 to 38.4 | percentage of participants | |
| Percentage of Patients Considered a Treatment Success at Week 12 as Assessed by the Clinical Global Impression of Change (CGIC) | SD-809 12 mg/Day | 28 | 95% Confidence Interval 18.5 to 40.8 | percentage of participants | |
| Percentage of Patients Considered a Treatment Success at Week 12 as Assessed by the Clinical Global Impression of Change (CGIC) | SD-809 24 mg/Day | 49 | 95% Confidence Interval 35.6 to 62.5 | percentage of participants | |
| Percentage of Patients Considered a Treatment Success at Week 12 as Assessed by the Clinical Global Impression of Change (CGIC) | SD-809 36 mg/Day | 44 | 95% Confidence Interval 31.4 to 56.7 | percentage of participants | |
| Change in the Modified Craniocervical Dystonia Questionnaire (mCDQ-24) Total Score From Baseline to Week 12 | Placebo | -7.1 | Standard Error 2.06 | units on a scale | |
| Change in the Modified Craniocervical Dystonia Questionnaire (mCDQ-24) Total Score From Baseline to Week 12 | SD-809 12 mg/Day | -5.8 | Standard Error 2.03 | units on a scale | |
| Change in the Modified Craniocervical Dystonia Questionnaire (mCDQ-24) Total Score From Baseline to Week 12 | SD-809 24 mg/Day | -10.2 | Standard Error 2.21 | units on a scale | |
| Change in the Modified Craniocervical Dystonia Questionnaire (mCDQ-24) Total Score From Baseline to Week 12 | SD-809 36 mg/Day | -10.7 | Standard Error 2.04 | units on a scale | |
| Percentage of Patients Considered a Treatment Success at Week 12 as Assessed by the Patient Global Impression of Change (PGIC) | Placebo | 31 | 95% Confidence Interval 20.6 to 43.8 | percentage of participants | |
| Percentage of Patients Considered a Treatment Success at Week 12 as Assessed by the Patient Global Impression of Change (PGIC) | SD-809 12 mg/Day | 23 | 95% Confidence Interval 14.4 to 35.4 | percentage of participants | |
| Percentage of Patients Considered a Treatment Success at Week 12 as Assessed by the Patient Global Impression of Change (PGIC) | SD-809 24 mg/Day | 45 | 95% Confidence Interval 31.9 to 58.7 | percentage of participants | |
| Percentage of Patients Considered a Treatment Success at Week 12 as Assessed by the Patient Global Impression of Change (PGIC) | SD-809 36 mg/Day | 40 | 95% Confidence Interval 28.1 to 53.2 | percentage of participants | |
| Percentage of Participants Who Had a 50% or Greater Reduction in Total Motor Abnormal Involuntary Movement Scale (AIMS) From Baseline to Week 12 | Placebo | 12 | 95% Confidence Interval 6.0 to 22.9 | percentage of participants | |
| Percentage of Participants Who Had a 50% or Greater Reduction in Total Motor Abnormal Involuntary Movement Scale (AIMS) From Baseline to Week 12 | SD-809 12 mg/Day | 13 | 95% Confidence Interval 6.9 to 24.2 | percentage of participants | |
| Percentage of Participants Who Had a 50% or Greater Reduction in Total Motor Abnormal Involuntary Movement Scale (AIMS) From Baseline to Week 12 | SD-809 24 mg/Day | 35 | 95% Confidence Interval 22.9 to 48.7 | percentage of participants | |
| Percentage of Participants Who Had a 50% or Greater Reduction in Total Motor Abnormal Involuntary Movement Scale (AIMS) From Baseline to Week 12 | SD-809 36 mg/Day | 33 | 95% Confidence Interval 21.8 to 45.9 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02291861/results